Indian IT and pharma stocks are not benefiting from a weaker rupee as expected. Tariff concerns are overshadowing currency gains. Investors are waiting for clarity on trade deals. Foreign investors have also been selling these stocks. Valuations remain a concern for pharma companies. Demand for IT services shows signs of improvement. Stock selection will be crucial for investors.
Related Posts
Rupee Touches Record Low Of 92.02 Against US Dollar, Closes Slightly Higher
- nationalpillarnews
- January 30, 2026
- 0
At the interbank foreign exchange, the rupee opened at 91.89 and gained ground, touching 91.82 against the greenback during intraday trade.
Embassy Developments Pre-Sales To Jump 2.5-Fold To Rs 5,000 Crore On Strong Housing Demand
- nationalpillarnews
- January 25, 2026
- 0
Embassy Developments clocked sales of Rs 2,031 crore last fiscal as against Rs 1,838 crore in 2023-24.
China halts sale of Sun Pharma drug used to treat dementia
- nationalpillarnews
- January 27, 2026
- 0
The National Medical Products Administration said a recent remote inspection found shortcomings in the company’s production processes, including in the prevention of contamination anfulfilmentd the […]